Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Industry Sets Out Priorities In Structured Dialog

Digitalization, Greater EU Alignment And Boosting Manufacturing Urged

Executive Summary

As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.

You may also be interested in...



Guntern Takes Lead At Medicines For Europe

Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.

What’s Next? Five Things To Look Out For In July

In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.

Industry Urges EU To Up Its Game On Manufacturing

While the European off-patent industry has welcomed the latest update to the EU’s industrial strategy, including a detailed analysis of European dependencies on the global API manufacturing network, it has urged the European Commission to go further and provide “tailored actions” to bolster local manufacturing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel